In this interview, Dr. Gary Pestano and Dr. Prithwish Pal discuss the advantages ddPCR offers in molecular residual disease ...

Hematuria may occur in up to 10% of the general population and results in costly evaluation to ensure it is of no consequence, i.e., no bladder cancer (BCa) is present since hematuria is typically the ...

Allogene Therapeutics has announced an expanded collaboration with Foresight Diagnostics to develop a minimal residual disease (MRD) assay as a companion diagnostic tool for identifying patients with ...

Despite major therapeutic advances, breast cancer remains prone to recurrence, particularly in patients with early-stage ...

(RTTNews) - Akoya Biosciences, Inc. (AKYA), Thursday announced the launch of a new multiplex immunofluorescence or mIF assay to advance antibody-drug conjugate or ADC development in breast cancer, ...

Persistent outcome disparities, particularly worse prognoses for Black women with breast cancer, persist even within the same genomic risk categories. Effective management requires integrating genomic ...

Please provide your email address to receive an email when new articles are posted on . A 14-gene molecular assay may help predict adjuvant chemotherapy benefit in early NSCLC. Patients assigned ...

Please provide your email address to receive an email when new articles are posted on . The CNSide assay aims to help clinicians with early diagnosis, treatment plans for those with CNS cancers. The ...